Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.53 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.51 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.51 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4229372 | 0.85 | KDM2B (0.50) | HRH3PARP15PARP10PARP2MAPK1 | |
| SCHEMBL7581468 | 0.85 | PARP15 (0.55) | PARP15PARP10PARP2SSTR5KCNH2 | |
| SCHEMBL416244 | 0.82 | PARP15 (0.72) | PARP15PARP10PARP2MAPK1NR1H4 | |
| SCHEMBL4240603 | 0.82 | HRH3 (0.51) | HRH3KCNH2 | |
| SCHEMBL14174984 | 0.81 | HRH3 (0.48) | HRH3 | |
| SCHEMBL2885506 | 0.79 | PARP10 (0.73) | PARP15PARP10PARP2MAPK1NR1H4 | |
| SCHEMBL12420703 | 0.79 | PARP10 (0.73) | PARP15PARP10PARP2NR1H4 | |
| SCHEMBL384351 | 0.79 | GPR119 (0.60) | SRD5A2 | |
| SCHEMBL15539329 | 0.79 | SSTR5 (0.55) | HRH3PARP15PARP10PARP2SSTR5 | |
| SCHEMBL4228646 | 0.79 | HRH3 (0.70) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| CN-101198604-A | NPY antagonists, their preparation and use | CEREP (FR) | 2008-06-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | HRH3 210/4885PARP15 2421/4885PARP10 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.